[go: up one dir, main page]

EA201591663A1 - Бесклеточная противококлюшная вакцина - Google Patents

Бесклеточная противококлюшная вакцина

Info

Publication number
EA201591663A1
EA201591663A1 EA201591663A EA201591663A EA201591663A1 EA 201591663 A1 EA201591663 A1 EA 201591663A1 EA 201591663 A EA201591663 A EA 201591663A EA 201591663 A EA201591663 A EA 201591663A EA 201591663 A1 EA201591663 A1 EA 201591663A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cellular
pertussis
present
vaccine
pulmonary
Prior art date
Application number
EA201591663A
Other languages
English (en)
Other versions
EA030749B1 (ru
Inventor
Ян Тенис Полман
Original Assignee
Круселл Холланд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В. filed Critical Круселл Холланд Б.В.
Publication of EA201591663A1 publication Critical patent/EA201591663A1/ru
Publication of EA030749B1 publication Critical patent/EA030749B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к композиции бесклеточной противококлюшной (аР) вакцины, содержащей антигены Bordetella pertussis: коклюшный анатоксин (РТ), филаментозный гемагглютинин (FHA) и фимбрии типов 2 и 3 (FIM), и необязательно пертактин (PRN), где FIM присутствует в количестве 12-100 мкг из расчета на дозу для человека.
EA201591663A 2013-03-08 2014-03-06 Бесклеточная противококлюшная вакцина EA030749B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361774993P 2013-03-08 2013-03-08
EP13169328 2013-05-27
PCT/EP2014/054379 WO2014135651A1 (en) 2013-03-08 2014-03-06 Acellular pertussis vaccine

Publications (2)

Publication Number Publication Date
EA201591663A1 true EA201591663A1 (ru) 2016-01-29
EA030749B1 EA030749B1 (ru) 2018-09-28

Family

ID=48470836

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591663A EA030749B1 (ru) 2013-03-08 2014-03-06 Бесклеточная противококлюшная вакцина

Country Status (22)

Country Link
US (2) US8916173B2 (ru)
EP (1) EP2863943B1 (ru)
JP (1) JP6282673B2 (ru)
KR (1) KR102236498B1 (ru)
CN (1) CN105007936B (ru)
AP (1) AP2015008702A0 (ru)
AU (1) AU2014224556B2 (ru)
BR (1) BR112015021523A8 (ru)
CA (1) CA2903937C (ru)
CL (1) CL2015002513A1 (ru)
DK (1) DK2863943T3 (ru)
EA (1) EA030749B1 (ru)
ES (1) ES2597832T3 (ru)
IL (1) IL241271A (ru)
MX (1) MX362793B (ru)
MY (1) MY172181A (ru)
NZ (1) NZ630868A (ru)
PE (1) PE20151720A1 (ru)
PH (1) PH12015501875A1 (ru)
SG (1) SG11201506858SA (ru)
TW (1) TWI630915B (ru)
WO (1) WO2014135651A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2596919C2 (ru) * 2015-01-16 2016-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
KR102426041B1 (ko) 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
KR102362777B1 (ko) 2018-03-27 2022-02-15 주식회사 녹십자 친화성 크로마토그래피 공정을 포함하는 백일해균 유래 단백질 수득 방법
CN112996538B (zh) * 2018-11-06 2025-07-08 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
KR20230011916A (ko) * 2020-03-09 2023-01-25 다이나박스 테크놀로지 코퍼레이션 파상풍, 디프테리아 및 백일해에 대한 능동 부스터 면역화
WO2024064579A1 (en) * 2022-09-20 2024-03-28 Ohio State Innovation Foundation Immunogenic proteins from bordetella pertussis
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8412207D0 (en) 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8516442D0 (en) 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3528006A1 (de) 1985-08-05 1987-02-05 Degussa Verfahren zur herstellung von epoxidierten organosiliziumverbindungen
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
GB8601279D0 (en) 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
DE3781541T2 (de) 1986-12-23 1993-05-06 Univ Leland Stanford Junior Modifiziertes pertussistoxin.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
WO1989001976A1 (en) 1987-09-04 1989-03-09 Amgen Inc. Recombinant dna-derived bordetella toxin subunit analogs
US7144576B1 (en) 1987-09-04 2006-12-05 Amgen, Inc. Modified pertussis toxin
IT1223334B (it) 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA1341123C (en) 1988-10-27 2000-10-17 David A. Relman Filamentous hemagglutinin of b. pertussis
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
DK0396964T3 (da) 1989-04-28 1995-10-30 Sclavo Spa Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
DE69025375T2 (de) 1989-11-06 1996-08-01 Smithkline Beecham Biolog Verfahren
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
ATE129159T1 (de) 1990-02-12 1995-11-15 Smithkline Beecham Biolog Impfstoff.
GB9007657D0 (en) 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6444211B2 (en) 1991-04-03 2002-09-03 Connaught Laboratories, Inc. Purification of a pertussis outer membrane protein
AU662783B2 (en) 1992-01-08 1995-09-14 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Whooping cough vaccine
ES2130265T3 (es) 1992-05-06 1999-07-01 Harvard College Region de union al receptor de la toxina difterica.
ES2118963T3 (es) 1992-05-23 1998-10-01 Smithkline Beecham Biolog Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
DE69327534T2 (de) 1992-06-18 2000-06-08 The President And Fellows Of Harvard College, Cambridge Impfstoffe gegen diphtherietoxin
AU678613B2 (en) 1993-09-22 1997-06-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FI951970L (fi) 1995-04-25 1996-10-26 Borealis As Olefiinipolymeerit, jotka sisältävät polaarisia ryhmiä, ja menetelmä niiden valmistamiseksi
EP1405643A1 (en) 1995-05-04 2004-04-07 Aventis Pasteur Limited Acellular pertussis vaccines and methods of preparation thereof
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
DK0914153T3 (da) * 1996-07-02 2007-01-29 Sanofi Pasteur Ltd Multivalente DTP-poliovacciner
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6475754B1 (en) 1999-05-14 2002-11-05 University Of Tennessee Research Corporation Polynucleotides encoding Bordatella bronchiseptica fimbrial proteins (FimN), vectors, and expression systems therefor
MY133981A (en) 2000-06-29 2007-11-30 Smithkline Beecham Biologicals S A Vaccine composition
EP1174505A1 (en) * 2000-06-30 2002-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur (Poly)peptides for the preparation of vaccines against Bordetella pertussis and/or Bordetella parapertussis, vaccines based upon such (poly)peptides, and antibodies against such peptides
GB0018031D0 (en) 2000-07-21 2000-09-13 Microbiological Res Authority Improvements relating to vaccines containing bordetella pertussis antigen
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
DK2454364T3 (da) 2009-07-16 2014-07-21 Crucell Holland Bv Fremstilling af poliovirus ved høje titre til vaccinefremstilling
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.

Also Published As

Publication number Publication date
PH12015501875A1 (en) 2015-12-07
IL241271A (en) 2016-07-31
US20150086586A1 (en) 2015-03-26
IL241271A0 (en) 2015-11-30
PE20151720A1 (es) 2015-12-10
KR102236498B1 (ko) 2021-04-06
CA2903937A1 (en) 2014-09-12
CL2015002513A1 (es) 2016-05-27
MX362793B (es) 2019-02-13
EA030749B1 (ru) 2018-09-28
SG11201506858SA (en) 2015-09-29
CN105007936B (zh) 2018-10-02
DK2863943T3 (en) 2016-11-07
EP2863943B1 (en) 2016-07-13
BR112015021523A2 (pt) 2017-07-18
AU2014224556B2 (en) 2016-10-06
NZ630868A (en) 2017-02-24
AU2014224556A1 (en) 2015-09-17
CA2903937C (en) 2021-11-09
US8916173B2 (en) 2014-12-23
MY172181A (en) 2019-11-15
BR112015021523A8 (pt) 2021-06-29
TWI630915B (zh) 2018-08-01
EP2863943A1 (en) 2015-04-29
TW201440786A (zh) 2014-11-01
WO2014135651A1 (en) 2014-09-12
CN105007936A (zh) 2015-10-28
MX2015011879A (es) 2016-01-08
ES2597832T3 (es) 2017-01-23
US20140255446A1 (en) 2014-09-11
JP6282673B2 (ja) 2018-02-21
JP2016510056A (ja) 2016-04-04
AP2015008702A0 (en) 2015-09-30
KR20150124973A (ko) 2015-11-06

Similar Documents

Publication Publication Date Title
EA201591663A1 (ru) Бесклеточная противококлюшная вакцина
MX2020011717A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MA44238B1 (fr) Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
PH12015501519A1 (en) Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
EA202090699A2 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
MX388128B (es) Vacuna combinada para cerdos.
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2016001695A (es) Composiciones inmunogenas de combinacion.
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
CL2013002219A1 (es) Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
ES2503516R1 (es) Complejo inmunogénico para vacunación y método de obtención
MX2016007224A (es) Vacuna contra el circovirus porcino tipo 2.
BR112013023354A2 (pt) vacina para rinite equina
WO2010080188A3 (en) Epitope targeted anthrax vaccine
EA201070014A1 (ru) Внутрикожная вакцина против гриппа